

LSU HSC-New Orleans Institutional Biosafety Committee
Meeting Minutes

Date: Wednesday, September 9, 2026
Time: 1:04 PM – 2:54PM
Location: Zoom

Members Present:

1. Zea, *IBC Chair*
2. Catling, *IBC Vice Chair*
3. Aiyar
4. Siggins
5. Caro, *Animal Containment*
6. Baker
7. Didier Mejia, *BSO*
8. Wang
9. Mason, *Local Non-affiliated Member*
10. Zabaleta
11. Yue
12. Foster

Members Excused:

1. Guidry, *Local Non-affiliated Member*

Other Individuals Attendance:

1. Porche, *VCAA*
2. Constans, *Director ORS*
3. Fuselier, *Research Compliance Analyst II, IACUC/IBC*
4. Pourciau, *Affiliated EH&S*
5. Burkett, *Affiliated EH&S*

1:04pm **Quorum Present**
The IBC has 13 voting members and 7 are required to conduct business

1:04pm **Call to Order**
The IBC Chair called the meeting to order

1:04pm **Conflicts of Interest**
The IBC Chair reminded all members present to identify any conflicts of interest as each application is reviewed.

1:05pm **Review and approval of previous meeting minutes**

- August 12, 2026

A motion was made and seconded to approve the minutes as written. Motion carried.
These minutes were posted on the ORS IBC webpage.

1:06pm **Review of Prior Business**

- The committee was reminded that the IBC Member SharePoint site serves as a centralized location for committee training materials, SOPs, and other reference documents. Non-affiliate access to

the SharePoint site was discussed, and IT was contacted regarding access. It was noted that external affiliates may need to be registered in the external affiliate database before IT can provide SharePoint access.

- The proposed change to the DMR process was discussed, including allowing additional time for the full committee to review protocols when requested.

1:09pm **New Business**

- Draft NIH Policy for Research Involving Biohazards:
 - The committee was informed of proposed changes to the NIH Policy for Research with Biohazards. Members were encouraged to review the proposed changes and submit comments to NIH. Potential impacts to institutional policies were discussed, including a proposed four-year Assurance Document submission cycle and a three-year maximum duration for IBC protocols.
- Kuali Education – “Protocols Assigned to Me” and “Submit Review”
 - Committee members received guidance on using the Protocols Assigned to Me tab in Kuali, including how to use Submit Review to clear completed assignments and reduce unnecessary email notifications. Members were also shown how to determine whether they are assigned as a Primary or Secondary reviewer by accessing the General Action Items section.
- IBC Committee Workload
 - Dr. Constans reported that he had met separately with Dr. Zea and Didier Mejia to assess the committee’s workload. While the volume of email notifications was identified as a potential concern for some members, a review of the number of protocols and assignments indicated that the overall workload was appropriate for the BSO and other committee members.

1:30pm **Review of Incidents & Non-compliance**

- **Administrative Closures Due to Inactivity from August 13, 2026 to September 9, 2026**

Title	Number	PI Name	Review Type	Continuing Review Date	Expiration Date
Biomechanical comparison between Bioabsorbable, Magnesium, and Stainless-Steel Screws in the execution of periacetabular osteotomies.	7456	Clement, Rutledge	Renewed	July 16th 2026	Jul 16, 2029
Docosanoids modulate homeostasis and cell survival after ischemic stroke	4471	Bazan, Nicolas	Renewed/Amended	Jul 01, 2026	Jul 01, 2027

- **Protocols that are suspended, in “Grace Period” and destined for administrative closure:**

Title	Number	PI Name	Review Type	Continuing Review Date	Expiration Date
-------	--------	---------	-------------	------------------------	-----------------

Neuronal Activity-Regulated Glutamine Transporter	9461	Erickson, Jeffrey	Amended	August 18, 2026	August 18, 2030
Serotonin receptor mediated intraocular pressure assessments	7578	Nichols, Charles	Renewed	September 03, 2026	September 03, 2029
Assessing drug discrimination through changes in ultrasonic vocalization in adult rats	5160	Nichols, Charles	Renewed/Amended	July 31, 2026	July 31, 2028
Neuroinflammation in CKD	5653	Mohandas, Rajesh	Amended	August 30, 2026	August 30, 2028
Interaction of Biopsychosocial Stress, Alcohol Misuse, and Post-Acute Neurobehavioral Sequelae of COVID-19	4557	Ferguson, Tekeda	Renewed/Amended	August 15, 2026	August 15, 2027

1:31pm **Inspections/Ongoing Oversight**

- EH&S**

- A laboratory inspection identified that Dr. Tsien does not currently have an approved IBC protocol. Dr. Tsien reported that no laboratory research activities have been conducted since Spring 2026. She plans to resume laboratory activities in January 2027 and will therefore be required to submit an IBC protocol for review and approval prior to resuming research. The protocol must be submitted by the December IBC meeting deadline.

1:35pm **IBC Registrations & Amendments for Review**

- Applications and amendments determined by the Chair or IBC Coordinator that do not fall under the NIH Guidelines for FCR**
 - New Protocols**

IBC: #11300	Plasma metabolites and ADRD-Related Biomarkers in the Context of HIV and Alcohol Use Disorder Risk
PI Name	Biose, Ifechukwude
Project Overview	The main goal is to determine whether HIV and alcohol use together increase the risk of early cognitive problems. The study will also identify blood-based markers that may help explain why this happens and could eventually help identify people at greater risk and guide strategies to prevent or delay cognitive decline.
NIH Guidelines Section(s)	N/A
Risk Assessment & Discussion	Personnel working in the laboratory will use an appropriate BSL-2 Biosafety cabinet and will use personal protective equipment (PPE), including gloves, eye goggles, and lab coats or disposable gowns. Proper SOPs were reviewed by BSO for handling patient samples.
Training	All institutional trainings required are complete for lab staff listed in the registration: - COI in Research - Laboratory Safety

	• IBC Compliance • BBP High Risk • Shipping Biological Materials
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2
IRB status (if applicable)	Application submitted and revisions are in progress
IBC Vote	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.

IBC: #11358	Multi-Omics Characterization of Elovand Rescue Responses in Neurons and Astrocytes
PI Name	Bazan, Nicolas
Project Overview	This study aims to better understand how brain cells are damaged in neurodegenerative diseases such as Alzheimer's disease and to identify ways to protect them. We will use laboratory-grown neurons (the cells responsible for communication in the brain) and astrocytes (support cells that help maintain brain health) and expose them to conditions that mimic disease-related stress, including toxic amyloid-beta protein, and erastin, a compound that triggers cell injury.
NIH Guidelines Section(s)	N/A
Risk Assessment & Discussion	Personnel working in the laboratory will use an appropriate BSL-2 Biosafety cabinet and will use personal protective equipment (PPE), including gloves, eye goggles, and lab coats or disposable gowns.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk Shipping Biological Materials
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2

IRB and IACUC status (if applicable)	N/A
IBC Vote	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.

IBC: #11346	TET1 and Sex Differences in Alcohol Associated Liver Tumorigenesis
PI Name	Lin, Hui-Yi
Project Overview	Men are generally more likely than women to develop liver cancer, called hepatocellular carcinoma (HCC). However, this difference is not seen in liver cancer related to alcohol-associated liver disease (ALD/HCC). A gene called TET1 may play an important role in the biological differences between males and females by affecting DNA regulation and alcohol-related liver damage. Understanding how TET1 and female sex hormones influence the development and progression of ALD/HCC will provide important information for future laboratory and clinical studies. This research will evaluate whether sex differences are considered when studying ALD/HCC and may identify TET1 as a promising new target for treating this serious disease using animal experiments.
NIH Guidelines Section(s)	N/A
Risk Assessment & Discussion	N/A (Project Registration)
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk • Shipping Biological Materials
EH&S Assessment	N/A
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	N/A
IRB and IACUC status (if applicable)	N/A
IBC Vote	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.

IBC: #4789	Cardiovascular effects of nicotine and high fact diet
PI Name	Yue, Xinpeng
Project Overview	Amendment to add new materials (de-identified human plasma and placental tissues that will be obtained from University of Iowa) and add new experiments (examine the expression of

	microRNA and gene of interest in human plasma and placental tissues based on our results from HFD-fed mice where microRNA-mediated downregulation of gene of interest was observed)
NIH Guidelines Section(s)	N/A
Risk Assessment & Discussion	Personnel working in the laboratory will use an appropriate BSL-2 Biosafety cabinet and will use personal protective equipment (PPE), including gloves, eye goggles, and lab coats or disposable gowns.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk • Shipping Biological Materials
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2
IACUC status (if applicable)	Application Approved
IBC Vote	The IBC determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.

- **Amendments and Renewals (August 13, 2026 to September 9, 2026)**

Title	Number	PI Name	Submission Type	Expiration Date	IBC Amendment - C01 Description
Nitrogen Analysis of Fecal Samples	11254	Byerley, Lauri	Amended	August 03, 2031	Change in shipping
Targeting ADAM17 for Hypertension Associated Vascular Dementia	10689	Lazartigues, Eric	Amended	July 14, 2031	Change in personnel
Synaptic Transmission in Cerebellum, Cellular Mechanisms Underlying the Long-Term Potentiation of GABA Release	10632	Liu, Si-Qiong	Amended	June 01, 2031	Change in personnel.

Long-Term Effects of Adolescent Alcohol on Pain	8651	Gilpin, Nicholas	Amended	May 26, 2030	Change in personnel
pIgR Mice Breeding Colony	8352	Welsh, David	Amended	March 06, 2030	Change in personnel
miRNA targeting of hypertension and metabolic pathways	7604	Lazartigues, Eric	Amended	September 26, 2029	Change in personnel
Novel Neuroprotective lipid mediators for Ischemic Stroke	4639	Bazan, Nicolas	Amended	November 01, 2027	Change in personnel
RPE Messengers, Transcription and Photoreceptor	2523	Bazan, Nicolas	Amended	August 26, 2026	Change in personnel
Signal transduction in pathogenesis of fungi	2494	Wang, Ping	Amended	November 14, 2026	Change in personnel
Viral Oncology Research Lab – In Vitro Techniques	2473	West, John	Amended	December 06, 2027	Change in personnel
Viral Oncology Research Lab – Human Tissues	2470	Wood, Charles	Amended	December 21, 2026	Change in personnel
Nitrogen Analysis of Fecal Samples	11254	Byerley, Lauri	Amended	August 03, 2031	Change shipping
Targeting ADAM17 for Hypertension Associated Vascular Dementia	10689	Lazartigues, Eric	Amended	July 14, 2031	Change in personnel
Synaptic Transmission in Cerebellum, Cellular Mechanisms Underlying the Long-Term Potentiation of GABA Release	10632	Liu, Si-Qiong	Amended	June 01, 2031	Change in personnel
CARC Analytical Core	4450	Siggins, Robert	Amended	June 15, 2027	Change in personnel
Long-Term Effects of Adolescent Alcohol on Pain	8651	Gilpin, Nicholas	Amended	May 26, 2030	Change in personnel
Preventing alcohol seeking with a nonmuscle myosin II	9045	Gilpin, Nicholas	Amended	June 11, 2030	Change in personnel

inhibitor under clinical development					
Characterization of Inflammatory Markers of Serum Samples in Trauma and Burn patients	10285	Smith, Alison	Amended	Mar 12, 2031	Change in personnel
Oncolytic HSV therapy for cancer	10410	Kaur, Balveen	Amended	Mar 31, 2031	Addition of research material
Targeting ADAM17 maturation in resistant hypertension	2490	Lazartigues, Eric	Amended	Nov 15, 2026	Change in personnel
CARC Analytical Core	4450	Siggins, Robert	Amended	Jun 15, 2027	Change in personnel
Murine Models for Cancer Immunology and Immunotherapy	2469	Sanchez-Pino, Maria	Amended	Dec 21, 2027	Change in personnel
Multi-Omics Characterization of Elovanoic Rescue Responses in Neurons and Astrocytes	11358	Bazan, Nicolas	Amended	Aug 28, 2031	Change in personnel
The role of antiretroviral therapy in susceptibility to oral human papillomavirus (HPV) infection	7010	Cameron, Jennifer	Amended	Jun 05, 2029	Change in personnel
The Effects of Metabolic & Bariatric Surgery on Lipid Metabolism, MDSC, and Cancer Cell Biology	5810	Sanchez-Pino, Maria	Close Request	Oct 05, 2028	
Effects of StellaLife Oral Care Recovery Kit on Palatal Wound Healing After Free Gingival Graft	5494	Joshi, Vinayak	Close Request	Jul 13, 2028	

Role of alpha2 adrenergic receptor antagonism in treating misuse of fentanyl adulterated with xylazine	9419	Pahng, Amanda	Renewed	August 18, 2030	
CRISPR interference of essential gene function in Chlamydia trachomatis	9397	Shen, Li	Renewed	August 28, 2030	
Small Molecule Induced Skipping of MLH3 Exon Seven to Slow Progression of DNA Repeat Expansion Disorders	5671	Grabczyk, Edward	Renewed	September 06, 2028	
Genomic and Proteomic Architecture of Atherosclerosis	5644	Love, Gordon	Renewed	September 19, 2028	
Role of alpha2 adrenergic receptor antagonism in treating misuse of fentanyl adulterated with xylazine	9419	Pahng, Amanda	Renewed	August 18, 2030	
CRISPR interference of essential gene function in Chlamydia trachomatis	9397	Shen, Li	Renewed	August 28, 2030	
Halting repeat expansion in hMLH3/YG8sR mice using human-specific oligonucleotides-breeding protocol	7782	Grabczyk, Edward	Renewed	September 26, 2029	
Stereotactic injection of 6HODA and Preformed alpha-synuclein fibrils for Parkinson's model	7462	Bazan, Nicolas	Renewed/Amended	Sep 06, 2029	Change in personnel
Peritumoral Neuroprotection induced by	9400	Bazan, Nicolas	Renewed/Amended	August 11, 2030	Change in personnel

Docosahexaenoic Acid administered in an Experimental in vivo murine model of Glioblastoma Multiforme					
Geroprotective Precision Medicine Strategies in PWH that Use Alcohol	9326	Welsh, David	Renewed/Amended	September 17, 2030	Change in personnel
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer	7695	Shen, Qiang	Renewed/Amended	October 01, 2029	Update IACUC and funding
Investigation of the anti-inflammatory effects of serotonin 5-HT2A receptor activation	7671	Nichols, Charles	Renewed/Amended	August 28, 2029	Change in personnel
Lactobacillus-vectored Alkaline Phosphatase to Mitigate Alcohol-Induced Leaky Gut and LPS Endotoxin Load in the Gut	7645	Welsh, David	Renewed/Amended	September 16, 2029	Change in personnel
Neuroprotective Effect of Docosanoids in Experimental Traumatic Brain Injury	5612	Bazan, Nicolas	Renewed/Amended	August 14, 2028	Update IACUC Change in personnel
Generation and characterization of CAR-expressed immune cells	4497	Monticone, Giulia	Renewed/Amended	August 25, 2027	Change in personnel
Peritumoral Neuroprotection induced by Docosahexaenoic Acid administered in an Experimental in vivo murine model of Glioblastoma Multiforme	9400	Bazan, Nicolas	Renewed/Amended	August 11, 2030	Change in personnel

Geroprotective Precision Medicine Strategies in PWH that Use Alcohol	9326	Welsh, David	Renewed/Amended	September 17, 2030	Change in personnel
Immunology and Respirometry of Burn Wounds and TBI Murine Model	5608	Smith, Alison	Renewed/Amended	Aug 29, 2028	Update start date

- Applications reviewed and Suspended (in Grace Period) by the Chair after modifications requested by FCR. Continuing IBC oversight is required with annual reviews.

N/A

- Full Committee Review of applications subject to *NIH Guidelines and our Policies*. Continuing IBC oversight required.

1:35pm

IBC #10988	Preclinical investigation of RON kinase receptor as a therapeutic target for TNBC and PDAC
PI Name	Ammanamanchi, Sudhakar
Project Overview	Our research identified key factors that regulate RON gene expression in breast and pancreatic cancer cells. We also found that RON is frequently associated with hypoxia-inducible factor-1 alpha (HIF-1α), a major regulator of genes involved in cancer cell survival, growth, invasion, and metastasis.
NIH Guidelines Section(s)	III-D-1-a
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk • Shipping Biological Materials
EH&S Assessment	The laboratory was inspected, and any identified deficiencies will be addressed prior to the initiation of research activities.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2 ABSL-2
IACUC status (if applicable)	Application ready for approval
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA)

1:51pm

	• Votes: 12/12 MRSA • COI: None reported Following a duly called vote of the committee, Dr. Ammanamanchi's protocol (deferred from August 12th FCR Meeting) was conditionally approved, pending submission and approval of the revisions requested by the Primary Reviewer.
IBC #11369	Preclinical Investigation of Oncolytic Virus and RON kinase Inhibitor for PDAC
PI Name	Ammanamanchi, Sudhakar
Project Overview	Pancreatic cancer is one of the most difficult cancers to treat. Current treatments, such as chemotherapy and radiation, can cause serious side effects, and many tumors eventually stop responding to them. One reason this cancer is so challenging is that tumors are surrounded by a protective barrier that makes it difficult for medicines and the body's immune system to reach and destroy cancer cells. To develop better treatments, researchers need to identify proteins that help pancreatic cancer grow and spread and find ways to overcome this barrier. One promising approach uses a virus modified by scientists called Vesicular Stomatitis Virus expressing Decorin gene (VSV-Decorin). This virus may change the tumor environment by reducing collagen, a protein that helps form the tissue surrounding tumors, making cancer cells more vulnerable to treatment. Another potential target is a protein called recepteur d origine nantais (RON).
NIH Guidelines Section(s)	III-D-1-a III-D-3-a
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk • Shipping Biological Materials
EH&S Assessment	The laboratory was inspected, and any identified deficiencies will be addressed prior to the initiation of research activities.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2 ABSL-2
IACUC status (if applicable)	Application ready for approval

2:08pm

IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA) • Votes: 10/10 MRSA • COI: None reported Following a duly called vote of the committee, Dr. Ammanamanchi's protocol was conditionally approved, pending submission and approval of the revisions requested by the Primary Reviewer. *Curran left the meeting, quorum maintained
IBC #11018	CELLULAR THERAPY IN CANCER AND NON MALIGNANT CONDITIONS
PI Name	Castro, Januario
Project Overview	The human immune system protects the body against infections and diseases by recognizing and destroying harmful cells. However, cancer cells develop mechanisms to escape immune surveillance and continue growing. One promising strategy to overcome this problem is CAR cell therapy, in which a patient's immune cells are genetically modified to recognize specific molecules found on the surface of cancer cells. We will develop safe and efficient methods for engineering immune cells; (2) generate CAR immune cells capable of recognizing disease-associated targets; and (3) evaluate their safety, function, and ability to selectively destroy target cells in laboratory models.
NIH Guidelines Section(s)	III-D-1-a III-E-1
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2
IRB or IACUC status (if applicable)	N/A
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA) • Votes: 10/10 MRSA • COI: None reported

2:22pm

	Following a duly called vote of the committee, Dr. Januario's protocol (deferred from August 12 th FCR Meeting) was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer. *Wang left the meeting, quorum maintained
IBC #11281	NOLANETS Biorepository 2026
PI Name	Maluccio, Mary
Project Overview	Collection of human tissues from patients with rare cancers. Including but not limited neuroendocrine cancer. For future clinical and/or research purposes.
NIH Guidelines Section(s)	N/A
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2
IRB status (if applicable)	Application approved
IBC Vote	The Primary Reviewer made a motion to assign the determination of Defer for Information • Votes: 10/10 Defer for Information • COI: None reported Following a duly called vote of the committee, Dr. Maluccio's protocol was Deferred for Information, pending submission of the requested revisions. The revised protocol will be reviewed and must receive approval by the Full Committee.
IBC #5043	Diagnostic and therapeutic approaches for the treatment of neuroendocrine tumors
PI Name	Lan, Michael
Amendment Overview	This amendment adds an alternative approach to establish a neuroendocrine prostate cancer model. Researchers will introduce an AKT1 expression construct into prostate cancer cells to investigate whether AKT1-mediated survival signaling supports stable neuroendocrine reprogramming driven by INSM1. The study will evaluate how AKT1, a signaling protein involved in cell

2:36pm

	growth and proliferation, may help cells tolerate the cellular stress associated with neuroendocrine differentiation.
NIH Guidelines Section(s)	III-D-1-a III-E-1 III-D-4
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2 ABSL-2
IACUC status (if applicable)	Application approved
IBC Vote	The Primary Reviewer made a motion to assign the determination of Defer for Information • Votes: 10/10 Defer for Information • COI: None reported Following a duly called vote of the committee, Dr. Lan's amendment was Deferred for Information, pending submission of the requested revisions. The revised protocol will be reviewed and must receive approval by the Full Committee.

2:42pm **Adjournment**

The IBC Chair moved to adjourn the meeting at 2:42PM. The next meeting is tentatively scheduled for Wednesday, October 14, 2025, via Zoom.